Charanjit Bountra
Director/Board Member at CannBioRex Pharmaceuticals Corp.
Profile
Charanjit Bountra is currently an Independent Director at CannBioRex Pharmaceuticals Corp., a Director at Kyttaro Ltd., and previously worked as Vice President & Head-Biology at GlaxoSmithKline, Inc. and as a Professor at the University of Oxford (Canada).
He also served as Chairman at Spinifex Group, Inc.
Charanjit Bountra active positions
| Companies | Position | Start |
|---|---|---|
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Director/Board Member | 2018-04-30 |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
| University of Oxford (Canada) | Corporate Officer/Principal | - |
KYTTARO Ltd.
 KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Director/Board Member | 2021-07-27 |
Former positions of Charanjit Bountra
| Companies | Position | End |
|---|---|---|
Spinifex Group, Inc.
 Spinifex Group, Inc. Advertising/Marketing ServicesCommercial Services Spinifex Group, Inc. provides advertising agency services. The private company is based in Torrance, CA. | Chairman | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Spinifex Group, Inc.
Spinifex Group, Inc. Advertising/Marketing ServicesCommercial Services Spinifex Group, Inc. provides advertising agency services. The private company is based in Torrance, CA. | Commercial Services |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Health Technology |
KYTTARO Ltd.
KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Health Technology |
- Stock Market
- Insiders
- Charanjit Bountra
